highperformr logo

Chugai Pharma USA, Inc.'s Overview

Total employees247
HeadquartersChuo-ku
Founded

Chugai Pharmaceutical Co., Ltd. is one of Japan’s leading research-based pharmaceutical companies, renowned for its strengths in biotechnology and antibody engineering. As a core member of the Roche Group, Chugai is dedicated to developing innovative drugs and services to address unmet medical needs globally, with a primary focus on oncology, bone and joint diseases, and renal diseases. Their mission is to add exceptional value by creating and delivering innovative medical products and services for the benefit of the medical community and human health around the world. Chugai strives for 'Innovation beyond imagination' to transform healthcare.

Where is Chugai Pharma USA, Inc.'s Headquarters?

HQ Function

The headquarters in Tokyo serves as the central hub for Chugai's global operations, overseeing strategic planning, corporate management, research and development direction, and administrative functions.

Notable Features:

Located in the modern Nihonbashi Muromachi Mitsui Tower, the headquarters likely features state-of-the-art facilities, advanced sustainable building technologies, and collaborative workspaces designed to foster innovation.

Work Culture:

Chugai's work culture emphasizes patient-centricity, innovation, and ethical practices. It fosters an environment of collaboration and continuous learning, encouraging employees to take on new challenges to realize 'Innovation beyond imagination'. Diversity and inclusion are also key aspects of their corporate culture.

HQ Significance:

The Tokyo headquarters is strategically important, anchoring Chugai's operations in its home market of Japan and serving as a critical link within the global Roche network. Its location in Nihonbashi, a prominent business district, underscores its status as a leading pharmaceutical company.

Values Reflected in HQ: The choice of a state-of-the-art facility in a historically significant and dynamic business hub reflects Chugai's commitment to leading-edge innovation, its deep Japanese roots, and its forward-looking global perspective.

Location:

Chugai Pharmaceutical operates globally, with a strong presence in Japan and key international markets. Its functions supported globally include research and development (with research sites in Japan and Singapore), manufacturing (primarily in Japan), clinical development (conducted worldwide including North America and Europe), and sales and marketing activities, often in collaboration with Roche. Chugai aims to deliver its innovative medicines to patients around the world, leveraging its own capabilities and the Roche Group's extensive network.

Street Address:

Nihonbashi Muromachi Mitsui Tower, 1-5-10 Nihonbashi-muromachi

City:

Chuo-ku

State/Province:

Tokyo

Country:

Japan

Chugai Pharma USA, Inc.'s Global Presence

New Jersey, USA

Address: One NewChange, London, EC4M 9AF, United Kingdom (Example for Chugai Pharma Europe Ltd. Actual US address for Chugai Pharma USA, Inc. is typically in Berkeley Heights, NJ or similar pharma hub)

To conduct clinical trials, engage with regulatory authorities like the FDA, and collaborate with medical experts and institutions in the United States, a key market for pharmaceutical innovation.

Singapore

Address: 3 Biopolis Drive, #05-11/12 Synapse, Singapore 138623

To leverage Singapore's vibrant biomedical research ecosystem and talent pool for cutting-edge drug discovery, contributing novel therapeutic candidates to Chugai's global pipeline.

London, United Kingdom

Address: Building 1, Chiswick Park, 566 Chiswick High Road, London W4 5YA, United Kingdom

To manage and execute clinical trials across European countries, secure regulatory approvals, and provide medical support for Chugai's therapies in the European market.

Buying Intent Signals for Chugai Pharma USA, Inc.

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Chugai Pharma USA, Inc.

As of April 2025, Chugai Pharma USA, Inc.' leadership includes:

Osamu Okuda - Representative Director, President and CEO
Toshiaki Itagaki - Representative Director, Executive Vice President, General Manager of Pharma F&D Div., General Manager of Digital & IT Supervisory Div.
Satoko Shisai - Executive Vice President, CFO, General Manager of Finance & Accounting Div., General Manager of Corporate Communications Dept.
Yasushi Ito - Executive Vice President, Co-Head of Project & Lifecycle Management Unit, General Manager of R&D Transformation Office
Shinya Furuya - Executive Vice President, Co-Head of Project & Lifecycle Management Unit, General Manager of Clinical Development Div.

Investors of Chugai Pharma USA, Inc.

Chugai Pharma USA, Inc. has been backed by several prominent investors over the years, including:

Roche Holding Ltd (Majority Shareholder)

Executive New Hires/Exits in the Last 12 Months

Hire5
Exits5

Chugai Pharmaceutical announced several key executive promotions and director changes effective early 2024, reflecting strategic leadership adjustments and board refreshment as part of its ongoing commitment to governance and growth.

Departures

William N. Anderson, William N. Anderson retired as Director (External) following the Ordinary General Meeting of Shareholders on March 27, 2024.
Paul H. Strebel, Paul H. Strebel retired as Director (External) following the Ordinary General Meeting of Shareholders on March 27, 2024.
Motoo Ueno, Motoo Ueno retired as Director (External), Audit and Supervisory Committee Member following the Ordinary General Meeting of Shareholders on March 27, 2024.
Kazuhiko Mizuno, Kazuhiko Mizuno retired as Director (External), Audit and Supervisory Committee Member following the Ordinary General Meeting of Shareholders on March 27, 2024.
Hiromichi Kimura, Hiromichi Kimura retired as Audit & Supervisory Board Member (External) following the Ordinary General Meeting of Shareholders on March 27, 2024.

New Appointments:

Yasushi Ito, Yasushi Ito promoted to Executive Vice President from Senior Vice President, Co-Head of Project & Lifecycle Management Unit.
Shinya Furuya, Shinya Furuya promoted to Executive Vice President from Senior Vice President, Co-Head of Project & Lifecycle Management Unit.
Masahide Ukita, Masahide Ukita appointed as Senior Vice President, Head of Translational Research Div.
Keiko Hongo, Keiko Hongo appointed as Senior Vice President, Head of Regulatory Science Div.
Miharu Koshiba, Miharu Koshiba newly appointed as Director (External), Audit and Supervisory Committee Member, effective March 27, 2024.

Technology (Tech Stack) used by Chugai Pharma USA, Inc.

Discover the tools Chugai Pharma USA, Inc. uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Chugai Pharma USA, Inc. Email Formats and Examples

Chugai Pharmaceutical Co., Ltd. primarily uses the email domain chugai-pharm.co.jp. While exact patterns can vary, a common format for corporate emails in Japan is [first].[last] or [first_initial][last].

[first].[last]@chugai-pharm.co.jp

Format

taro.yamada@chugai-pharm.co.jp

Example

75%

Success rate

News and media

Chugai Pharmaceutical Co., Ltd. Official WebsiteMarch 1, 2024

Chugai’s Enspryng Approved in Europe for the Treatment of NMOSD in Children Aged Six Years and Older

Chugai announced that the European Commission approved Enspryng (satralizumab) as the first and only treatment option for children aged six years and older with aquaporin-4 antibody (AQP4-IgG)-seropositive neuromyelitis optica spectrum disorder (NMOSD). This marks a significant advancement for pediatric patients with this rare autoimmune disease....more

Chugai Pharmaceutical Co., Ltd. Official WebsiteFebruary 29, 2024

Chugai Files New Drug Application for Nemolizumab for Atopic Dermatitis in Japan

Chugai filed a new drug application with the Japanese Ministry of Health, Labour and Welfare for nemolizumab, an anti-interleukin-31 (IL-31) receptor A humanized monoclonal antibody, for the treatment of pruritus associated with atopic dermatitis in adult and adolescent patients. This follows positive results from Phase III clinical trials....more

Chugai Pharmaceutical Co., Ltd. Official WebsiteFebruary 7, 2024

Chugai Reports Financial Results for 2023 and Forecasts for 2024

Chugai announced its consolidated financial results for the fiscal year ended December 31, 2023, reporting Core EPS of 219.0 yen. The company highlighted strong performance driven by its global products and outlined its financial forecasts and strategic priorities for 2024, emphasizing continued R&D investment and growth....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Chugai Pharma USA, Inc., are just a search away.